

# **Pediatric Brain Tumor Foundation of the United States, Inc.**

---

**Financial Statements**

**Years Ended December 31, 2017 and 2016**

## **Table of Contents**

<b>Independent Auditors' Report</b> .....	1
<b>Financial Statements:</b>	
Statements of Financial Position .....	2
Statements of Activities .....	3
Statements of Functional Expenses.....	5
Statements of Cash Flows .....	7
Notes to the Financial Statements .....	8



## **Independent Auditors' Report**

Members of the Board of Directors  
Pediatric Brain Tumor Foundation of the United States, Inc.  
Asheville, North Carolina

### ***Report on the Financial Statements***

We have audited the accompanying statements of financial position of the Pediatric Brain Tumor Foundation of the United States, Inc. (the "Foundation") as of December 31, 2017 and 2016, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

### ***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' Responsibility***

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Foundation's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Opinion***

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Pediatric Brain Tumor Foundation of the United States, Inc. at December 31, 2017 and 2016, and the changes in its net assets and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

*Dixon Hughes Goodman LLP*  
**Asheville, North Carolina**  
**April 19, 2018**

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Statements of Financial Position**  
**December 31, 2017 and 2016**

	<u>2017</u>	<u>2016</u>
<b>ASSETS</b>		
Cash and cash equivalents	\$ 595,637	\$ 440,730
Investments	1,418,668	1,809,865
Accounts receivable	119,626	140,626
Contributions receivable	15,930	20,615
Other assets	117,148	90,022
Property and equipment, net	<u>123,804</u>	<u>129,419</u>
Total assets	<u>\$ 2,390,813</u>	<u>\$ 2,631,277</u>
<b>LIABILITIES AND NET ASSETS</b>		
Liabilities:		
Accounts payable and accrued expenses	\$ 151,779	\$ 156,825
Grants payable	<u>856,230</u>	<u>929,959</u>
Total liabilities	<u>1,008,009</u>	<u>1,086,784</u>
Net assets:		
Unrestricted:		
Board designated—quasi-endowment	1,016,243	1,716,243
Available for operations	<u>242,126</u>	<u>(295,137)</u>
Total unrestricted net assets	1,258,369	1,421,106
Temporarily restricted net assets	<u>124,435</u>	<u>123,387</u>
Total net assets	<u>1,382,804</u>	<u>1,544,493</u>
Total liabilities and net assets	<u>\$ 2,390,813</u>	<u>\$ 2,631,277</u>

See accompanying notes.

**Pediatric Brain Tumor Foundation of the United States, Inc.**

**Statements of Activities**

**Years Ended December 31, 2017 and 2016**

---

	<u>2017</u>		
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Total</u>
Revenues, gains, and other support:			
Public contributions	\$ 5,979,195	\$ 124,435	\$ 6,103,630
Less direct benefits to donors	(906,062)	-	(906,062)
Non-cash contributions	445,578	-	445,578
Investment income	203,173	-	203,173
Net assets released from restrictions	123,387	(123,387)	-
	<u>5,845,271</u>	<u>1,048</u>	<u>5,846,319</u>
Total revenues, gains, and other support			
	<u>5,845,271</u>	<u>1,048</u>	<u>5,846,319</u>
Expenses:			
Programs	4,553,433	-	4,553,433
Management and general	725,025	-	725,025
Fundraising	729,550	-	729,550
	<u>6,008,008</u>	<u>-</u>	<u>6,008,008</u>
Total expenses			
	<u>6,008,008</u>	<u>-</u>	<u>6,008,008</u>
Change in net assets	(162,737)	1,048	(161,689)
Net assets at beginning of year	<u>1,421,106</u>	<u>123,387</u>	<u>1,544,493</u>
Net assets at end of year	<u>\$ 1,258,369</u>	<u>\$ 124,435</u>	<u>\$ 1,382,804</u>

See accompanying notes.

---

<b>2016</b>		
<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Total</b>
\$ 5,765,502	\$ 123,387	\$ 5,888,889
(848,680)	-	(848,680)
458,680	-	458,680
88,894	-	88,894
<u>127,104</u>	<u>(127,104)</u>	<u>-</u>
 5,591,500	 (3,717)	 5,587,783
 4,263,523	 -	 4,263,523
708,660	-	708,660
<u>648,393</u>	<u>-</u>	<u>648,393</u>
 <u>5,620,576</u>	 <u>-</u>	 <u>5,620,576</u>
 (29,076)	 (3,717)	 (32,793)
<u>1,450,182</u>	<u>127,104</u>	<u>1,577,286</u>
 <u>\$ 1,421,106</u>	 <u>\$ 123,387</u>	 <u>\$ 1,544,493</u>

**See accompanying notes.**

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Statements of Functional Expenses**  
**Years Ended December 31, 2017 and 2016**

	2017				
	Program	Management and General	Fundraising	Total Supporting Services	Total
Salaries and related expenses	\$ 1,737,530	\$ 409,584	\$ 472,857	\$ 882,441	\$ 2,619,971
Research grants	1,355,897	-	-	-	1,355,897
Direct aid to families	421,851	-	-	-	421,851
Scholarship awards	85,874	-	-	-	85,874
Awards and honorariums	3,681	35	267	302	3,983
Conferences	75,125	3,482	3,113	6,595	81,720
Services	154,428	21,732	18,594	40,326	194,754
Office expenses	20,056	13,105	2,472	15,577	35,633
Equipment rental	5,594	1,413	3,298	4,711	10,305
Video	2,852	200	15	215	3,067
Advertising	23,910	1,596	1,305	2,901	26,811
Repairs and maintenance	-	4,446	-	4,446	4,446
Rent and utilities	112,583	24,637	27,856	52,493	165,076
Telephone	20,681	9,969	4,600	14,569	35,250
Auto expense	52,034	6,269	4,458	10,727	62,761
Travel	238,809	42,384	45,683	88,067	326,876
Supplies	994	58	125	183	1,177
Training	276	6,912	203	7,115	7,391
Professional fees	-	22,300	-	22,300	22,300
Insurance	24,712	12,779	4,615	17,394	42,106
Printing and postage	121,588	8,085	50,706	58,791	180,379
Fees and licenses	43,179	77,868	29,219	107,087	150,266
IT services	21	16,897	-	16,897	16,918
Depreciation	40,884	10,692	11,321	22,013	62,897
Other	10,874	30,582	48,843	79,425	90,299
Total expenses before direct benefits to donors	4,553,433	725,025	729,550	1,454,575	6,008,008
Direct benefits to donors	-	-	-	-	906,062
Total expenses	<u>\$ 4,553,433</u>	<u>\$ 725,025</u>	<u>\$ 729,550</u>	<u>\$ 1,454,575</u>	<u>\$ 6,914,070</u>

See accompanying notes.

**2016**

<b>Program</b>	<b>Management and General</b>	<b>Fundraising</b>	<b>Total Supporting Services</b>	<b>Total</b>
\$ 1,509,384	\$ 426,603	\$ 395,334	\$ 821,937	\$ 2,331,321
1,265,615	-	-	-	1,265,615
436,027	-	-	-	436,027
89,750	-	-	-	89,750
2,386	-	288	288	2,674
85,254	-	-	-	85,254
112,133	19,177	14,951	34,128	146,261
16,947	16,904	1,769	18,673	35,620
5,198	1,522	2,887	4,409	9,607
3,094	-	700	700	3,794
16,542	577	1,590	2,167	18,709
235	6,562	-	6,562	6,797
157,095	35,303	41,107	76,410	233,505
19,998	7,447	5,127	12,574	32,572
52,993	2,429	6,617	9,046	62,039
246,677	14,563	20,824	35,387	282,064
788	-	-	-	788
1,225	1,775	87	1,862	3,087
36,905	26,622	3,779	30,401	67,306
23,301	9,283	3,971	13,254	36,555
104,942	5,640	60,866	66,506	171,448
30,900	55,608	27,430	83,038	113,938
218	25,144	-	25,144	25,362
40,748	10,655	11,284	21,939	62,687
5,168	42,846	49,782	92,628	97,796
4,263,523	708,660	648,393	1,357,053	5,620,576
-	-	-	-	848,680
\$ 4,263,523	\$ 708,660	\$ 648,393	\$ 1,357,053	\$ 6,469,256

See accompanying notes.



**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Statements of Cash Flows**  
**Years Ended December 31, 2017 and 2016**

	<u>2017</u>	<u>2016</u>
Cash flows from operating activities:		
Change in net assets	\$ (161,689)	\$ (32,793)
Adjustments to reconcile change in net assets to net cash used by operating activities:		
Depreciation	62,897	62,687
Net realized and unrealized gains on investments	(156,333)	(41,416)
Changes in assets and liabilities:		
Accounts receivable	21,000	(13,513)
Contributions receivable	4,685	3,005
Other assets	(27,126)	398
Accounts payable and accrued expenses	(5,046)	(45,235)
Grants payable	(73,729)	(188,662)
Net cash used by operating activities	<u>(335,341)</u>	<u>(255,529)</u>
Cash flows from investing activities:		
Purchases of investments	-	(61,840)
Sales of investments	547,530	275,000
Purchase of property and equipment	(57,282)	(26,436)
Net cash provided by investing activities	<u>490,248</u>	<u>186,724</u>
Net increase (decrease) in cash and cash equivalents	154,907	(68,805)
Cash and cash equivalents, beginning of year	<u>440,730</u>	<u>509,535</u>
Cash and cash equivalents, end of year	<u>\$ 595,637</u>	<u>\$ 440,730</u>

See accompanying notes.

## **Notes to the Financial Statements**

### **1. Summary of Significant Accounting Policies**

#### ***Organization***

The Pediatric Brain Tumor Foundation of the United States, Inc. (the “Foundation”) is a national non-profit organization dedicated to funding pediatric brain tumor research, increasing public awareness about the disease of pediatric brain tumors, and providing financial, educational and emotional support to the families of children with brain tumors.

The Foundation’s goals are achieved through the funding of scientific research projects at leading research facilities across the United States and internationally, that are related to the disease of childhood brain tumors. Research funds are granted through a scientific peer review process. Grants are provided to sponsor medical symposiums in the United States and internationally. The Foundation also provides grants designed to attract new researchers in the field of study.

With a special interest in promoting partnerships and collaborations in science, the Foundation has provided innovative funding, such as for the operations center of the Pacific Pediatric Neuro-Oncology Consortium (PNO) Clinical Trials housed at the University of California, San Francisco, in which fifteen of the leading pediatric brain tumor institutions participate.

The Foundation provides support to patients and their families through educational resources in a variety of medias: on its website, such as an online video learning series; through a new toolkit for newly diagnosed families, which provides disease information and a place for families to store and organize their child’s medical records, appointments, healthcare providers, scans, etc.; and through educational conferences in major cities across the country. The Foundation also provides emergency financial assistance to families in twelve states and college scholarships for survivors throughout the nation. New programs include bereavement support, peer support and family camps.

In 2014, the Foundation acquired the assets of the Brain Tumor Foundation for Children, Inc., a non-profit organization in Atlanta, Georgia, which provided financial assistance, social support, and information for families of children with brain and spinal cord tumors. The Foundation has continued with this mission, as agreed upon in the related purchase agreement, in the form of direct aid to families.

In 2016, the Foundation acquired the assets of Vs. Cancer, Inc., a nonprofit organization based in Raleigh, NC, which recruited sports teams to raise funds for childhood cancer research and hospital support programs. Also in 2016, the Foundation acquired the assets of We Can Pediatric Brain Tumor Network, a Los Angeles, California based nonprofit that provided information and emotional support for families of children with brain tumors. The Foundation has continued supporting the programs of these organizations, as agreed upon in related asset purchase agreements.

During the third year of the Foundation’s 2013-16 strategic plan, the Foundation made critical investments of financial and human capital to achieve six key objectives, including growing existing fundraising programs and creating new revenue sources to fund more research. The Foundation also intentionally invested in creating a network of local chapters to reach and serve more families affected by childhood brain tumors.

To diversify revenue beginning in 2014, the Foundation launched a new signature fundraising event, the Starry Night 8.5K walk/run; established new corporate partnerships; created an annual and major giving program to increase non-event revenue; and introduced low-cost, efficient online fundraising pages for community members and endurance athletes. The Ride for Kids® program worked with motorcycle industry experts to increase new and return participation; cross-promoted with the Starry Night program and added components to increase general community participation.

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

---

The Foundation's research investment strategy included establishing a framework for prioritizing funding; creating a Research Advisory Network to provide highly informed perspectives on the biomedical research enterprise; and broadening the scope of the Foundation's research funding and expertise. The Foundation began to expand family support program offerings, including hosting its first educational conference for survivors and parents. On the organizational side, the Foundation recruited new board members from the legal, financial services, insurance marketing and hospitality industries; increased board involvement in fundraising and established Chapter offices in Georgia and Illinois.

In 2014, the Foundation created an integrated marketing and communications plan; established stronger brand identity by developing branded websites, fundraising events and educational literature; and expanded communications resources to support new programs and initiatives such as chapters and online fundraising. The Foundation increased the use of social media to communicate mission-driven stories and developed new and updated educational resources for families.

***Method of reporting***

The Foundation's accounts are maintained, and these statements are presented, on the accrual basis of accounting to present the results of activities and financial position in conformity with accounting principles generally accepted in the United States of America ("GAAP").

The Foundation is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted, temporarily restricted, or permanently restricted net assets based on stipulations made by the donor. Temporarily restricted contributions received and expended in the same year are reported as unrestricted revenue rather than as temporarily restricted revenue. The Foundation has no permanently restricted net assets.

***Contributions***

Unconditional promises to give and contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support, depending on the existence and/or nature of donor restrictions.

The Foundation records gifts of property and equipment as unrestricted support unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used, as well as gifts of cash or other assets that must be used to acquire long-lived assets, are reported as restricted support. Absent explicit donor stipulations about how those long-lived assets must be maintained, the Foundation reports expirations of donor restrictions when the donated or purchased long-lived assets are acquired and/or placed in service.

Accordingly, the Foundation reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

Donated assets are recorded at fair market value on the date of receipt. A substantial number of unpaid volunteers have donated significant amounts of their time to the Foundation's programs. If donated services either created or enhanced non-financial assets or required specialized skills that would have to be purchased if not donated, the value of those donated services would be recorded. To that end, non-cash contributions of equipment, materials, motorcycles, food, and professional and other services in the amount of \$445,578 and \$458,680 are included in the 2017 and 2016 statements of activities, respectively.

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

---

***Functional expenses***

The Foundation allocates its expenses on a functional basis among its programs and supporting services. Expenses that can be identified with a specific program and support service are allocated directly according to their nature and expense classification. Other expenses that are common to several functions are allocated based upon management's best estimates of time spent or facilities used.

***Allocation of joint costs***

The Foundation conducted a direct mail campaign in 2016 that includes requests for contributions, as well as program components. The cost of conducting that campaign included approximately \$16,000 of joint costs for the year ended December 31, 2016, which are not specifically attributable to particular components of the campaign. For the year ended December 31, 2016, the Foundation allocated \$-0- to program expense and allocated \$8,195 to fundraising expense on the accompanying 2016 statement of activities. No such costs were allocated during the year ended December 31, 2017.

***Estimates***

The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the reporting date. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

***Cash and cash equivalents***

Cash and cash equivalents include cash on hand and amounts on deposit in financial institutions with original maturities of three months or less.

***Receivables***

The Foundation considers accounts receivable to be fully collectible; accordingly, no allowance for doubtful accounts is required. If amounts become uncollectable, they will be charged to operations when the determination is made.

***Investments***

Investments include cash and cash equivalents, money market funds, mutual funds, common stock, and corporate obligations and bond funds. Investments in equity securities with readily determinable fair value and all investments in debt securities are measured at fair value in the statements of financial position.

***Fair value measurements***

Fair value as defined under GAAP is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Foundation utilizes market data or assumptions that market participants would use in pricing the asset or liability. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

- Level 1:** Observable inputs such as quoted prices in active markets.
- Level 2:** Inputs other than quoted prices in active markets that are either directly or indirectly observable.
- Level 3:** Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

---

***Property and equipment***

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Depreciable lives range from three to seven years. The Foundation capitalizes and depreciates all capital expenditures in excess of \$500.

***Income taxes***

The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code; accordingly, the accompanying financial statements do not reflect a provision or liability for federal and state income taxes. The Foundation has determined that it does not have any material unrecognized tax benefits or obligations as of December 31, 2017.

***Concentration of credit risk***

The Foundation maintains bank accounts with various financial institutions throughout the United States. Accounts at each institution are insured by the Federal Deposit Insurance Corporation. At times, the Foundation has cash balances that exceed the insured amount. Management believes that the risks related to these deposits are minimal.

***New accounting pronouncement***

The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities*, to improve the presentation of financial statements of not-for-profit entities. The standard addresses key qualitative and quantitative matters including net asset classes, investment return, expenses, liquidity and availability of resources, and presentation of operating cash flows. The amendments in ASU 2016-14 are effective for annual financial statements issued for fiscal years beginning after December 15, 2017. The Foundation is evaluating any impacts on the financial statements that might result from application of this new standard.

***Subsequent events***

Subsequent events have been evaluated through April 19, 2018, which is the date the financial statements were available to be issued.

**2. Cash and Cash Equivalents**

For purposes of the statements of cash flows, the Foundation considers all short-term liquid investments with maturities of three months or less (except money market funds held in the investment portfolios) to be cash equivalents. See Note 6 for a further description of restricted cash.

At December 31, 2017 and 2016, cash and cash equivalents consist of the following:

	<u>2017</u>	<u>2016</u>
Cash	\$ 471,202	\$ 317,343
Restricted cash	<u>124,435</u>	<u>123,387</u>
Total	<u>\$ 595,637</u>	<u>\$ 440,730</u>

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

**3. Fair Value of Financial Assets**

Prices for certain investments such as common stock, money market funds, and mutual funds are readily available in active markets in which those securities are traded, and the resulting fair values are categorized as Level 1. Prices for corporate bonds are determined on a recurring basis based on inputs readily available in public markets or can be derived from information available in publicly quoted markets and are categorized as Level 2.

There were no changes, during the years ended December 31, 2017 and 2016, to the Foundation's valuation techniques used to measure asset and liability fair values on a recurring basis.

The following tables set forth by level within the fair value hierarchy the Foundation's financial assets accounted for at fair value on a recurring basis as of December 31, 2017 and 2016. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Foundation's assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. Assets at fair value as of December 31, 2017 and 2016 consist of the following:

	<b>Assets at Fair Value as of December 31, 2017</b>			
	<b>(Level 1)</b>	<b>(Level 2)</b>	<b>(Level 3)</b>	<b>Fair Value</b>
Money market funds	\$ 77,075	\$ -	\$ -	\$ 77,075
Mutual funds and ETFs:				
Bond funds	1,169,496	-	-	1,169,496
Corporate bonds and government securities	-	169,970	-	169,970
	<u>\$ 1,246,571</u>	<u>\$ 169,970</u>	<u>\$ -</u>	<u>\$ 1,416,541</u>
	<b>Assets at Fair Value as of December 31, 2016</b>			
	<b>(Level 1)</b>	<b>(Level 2)</b>	<b>(Level 3)</b>	<b>Fair Value</b>
Money market funds	\$ 59,623	\$ -	\$ -	\$ 59,623
Mutual funds and ETFs:				
Bond funds	1,436,828	-	-	1,436,828
Common stocks	994	-	-	994
Corporate bonds and government securities	-	312,137	-	312,137
	<u>\$ 1,497,445</u>	<u>\$ 312,137</u>	<u>\$ -</u>	<u>\$ 1,809,582</u>

The Foundation has \$2,127 and \$283 of cash and cash equivalents held in investment accounts as of December 31, 2017 and 2016, respectively, which was not classified as a level as prescribed within the provision.

The Foundation recognizes transfers between the levels as of the beginning of the reporting period. There were no transfers between the levels for the years ended December 31, 2017 and 2016.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future values. Furthermore, although the Foundation believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

The components of investment income for the years ended December 31, 2017 and 2016 are as follows:

	<u>2017</u>	<u>2016</u>
Interest and dividend income, net of investment cost	\$ 46,840	\$ 47,478
Net realized gains	62,706	29,973
Net unrealized gains	<u>93,627</u>	<u>11,443</u>
	<u>\$ 203,173</u>	<u>\$ 88,894</u>

**4. Property and Equipment**

At December 31, 2017 and 2016, property and equipment consist of the following:

	<u>2017</u>	<u>2016</u>
Computer equipment	\$ 188,661	\$ 175,443
Furniture	133,160	133,160
Telephone system	33,094	33,095
Leasehold improvements	143,410	99,345
Other office equipment	<u>334,510</u>	<u>334,510</u>
	832,835	775,553
Less accumulated depreciation	<u>(709,031)</u>	<u>(646,134)</u>
Property and equipment, net	<u>\$ 123,804</u>	<u>\$ 129,419</u>

**5. Grants Payable**

Grants payable at December 31, 2017 and 2016, include the following:

	<u>2017</u>	<u>2016</u>
Pediatric Brain Tumor Foundation Research Institute grants	\$ 718,730	\$ 321,529
Early Career Development and Opportunity Grants	137,500	475,000
Vs. Cancer grants	<u>-</u>	<u>133,430</u>
Grants Payable	<u>\$ 856,230</u>	<u>\$ 929,959</u>

**6. Temporarily Restricted Net Assets**

Temporarily restricted net assets at December 31, 2017 and 2016, consist of the following:

	<u>2017</u>	<u>2016</u>
Subsequent year Ride for Kids®	<u>\$ 124,435</u>	<u>\$ 123,387</u>

## **7. Quasi-Endowment**

The Foundation's quasi-endowment was organized to support the financial operations of the Foundation. The Foundation's board designated funds include amounts classified as unrestricted. During 2017, the Board elected to reduce the amount of the board designated funds by \$700,000, from \$1,716,243 to \$1,016,243 to fulfill research grant commitments. The Board resolved to adjust the board designated funds as needed for the reserve to be held at a minimum of 30 percent of annual budgeted expenses. As required by GAAP, net assets associated with endowment funds, including funds designated by the Board of Directors to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

### ***Interpretation of relevant law***

The Board of Directors of the Foundation has interpreted the North Carolina Uniform Prudent Management of Institutional Funds Act (the "Act") as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Foundation has classified as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulated is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by Foundation in a manner consistent with the standard of prudence prescribed by the Act. In accordance with the Act, the Foundation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

1. The duration and preservation of the fund
2. The purposes of the organization and the donor-restricted endowment fund
3. General economic conditions
4. The possible effect of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. The investment policies of the Foundation

### ***Return objectives and risk parameters***

The Foundation has adopted investment and spending policies for board designated assets that are intended to provide an ongoing stream of funding for financial assistance that is supported by the quasi-endowment. The quasi-endowment assets include assets of donor-restricted funds that the organization must hold in perpetuity as well as board-designated funds. Under this policy, as approved by the Board, the board designated assets are invested in a manner that is intended to produce a high level of total investment return consistent with a prudent level of portfolio risk. The Foundation expects its board designated funds, over time, to provide a rate of return similar to that of other investments of the Foundation.

### ***Strategies employed for achieving objectives***

To satisfy its long-term rate-of-return objectives, the Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Foundation targets a diversified asset allocation that includes fixed income instruments and equity-based investments to achieve its long-term return objectives within prudent risk constraints.



**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

---

**8. Net Assets Released from Restrictions**

Net assets released from restrictions for the years ended December 31, 2017 and 2016, consist of the following:

	<u>2017</u>	<u>2016</u>
Ride for Kids® contributions and sponsorships	<u>\$ 123,387</u>	<u>\$ 127,104</u>

**9. Commitments**

***Operating lease***

The Foundation has an operating lease agreement for the rental of office space in Asheville, North Carolina; Atlanta, Georgia; and Raleigh, North Carolina. Rent expense totaled \$150,199 and \$220,711 for the years ended December 31, 2017 and 2016, respectively. The agreement for the Asheville space expires in March 2024. The agreement for the Atlanta space was renewed in 2015 and will expire in July 2020. The agreement for the Raleigh space expires in October in October 2019. Annual future minimum payments are as follows for the next five years ending December 31,

2018	\$ 154,059
2019	155,315
2020	133,193
2021	114,533
2022	<u>116,846</u>
	<u>\$ 673,946</u>

***Conditional grants***

In 2014, three \$1 million grants were approved to existing research facilities for the purpose of funding a multi-year research program. Actual funding of these grants was paid out to the grant recipients in installments for three years beginning in 2015 and ending in December 2017. Anticipated grant payments of \$718,730 have been included in grants payable at December 31, 2017 and represent the final payments under the grants.

In December 2015, the Foundation approved three grants to be awarded in the amount of \$100,000 each, one grant in the amount of \$250,000, and one grant in the amount of \$50,000 for either Early Career Development or Opportunity Award grants. Anticipated grant payments of \$137,500 have been included in grants payable at December 31, 2017 and represent the final payments under the grants.

In February 2018, the Foundation also approved a grant to be awarded in the amount of \$100,000 to an existing research facility. The payment schedule for this grant agreement includes equal quarterly payments of \$25,000 beginning in February 2018. However these grant payments are contingent upon conditions and have therefore been excluded from the grants payable liability as of December 31, 2017.

**10. Retirement Plan**

The Foundation sponsors a 401(k) defined contribution pension plan covering all its employees. The Foundation matches 100% of eligible employee contributions up to 3% of employees' annual compensation plus 50% of eligible employee contributions up to 6% of the employees' annual compensation. The employees are immediately vested in their contributions. Foundation matching contributions begin when an employee begins contributing and are 100% vested immediately. Profit sharing contributions, in an amount to be determined by the

**Pediatric Brain Tumor Foundation of the United States, Inc.**  
**Notes to the Financial Statements**

---

Foundation each year, begin after one year of service eligibility requirement is met. Retirement plan expense amounted to \$48,399 and \$45,984 for the years ended December 31, 2017 and 2016, respectively.

**11. Related Party Transactions**

During 2017 and 2016, approximately \$-0- and \$46,000, respectively, in legal fees were donated by a member of the Board of the Foundation. These amounts are included in professional fees and non-cash contributions.

**12. Risks and Uncertainties**

A significant portion of the Foundation's assets is held in various investment options. Investment securities are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is possible that changes in values of investment securities will occur and that such changes could materially affect the amounts reported in the financial statements.

**13. Subsequent Events**

The Foundation entered into an Asset Purchase Agreement on March 6, 2018 to assume substantially all of the assets and liabilities of Pediatric Low Grade Astrocytoma Foundation, Inc. This organization is a non-profit organization in Massachusetts, which provides research, support, and information for families of children with pediatric low-grade gliomas brain tumors. The Foundation will continue with this mission, as agreed upon in the related Asset Purchase Agreement. Approximately \$3,000,000 in cash will be transferred to the Foundation once the acquisition is finalized. This cash will be considered temporarily restricted for existing programs.